Clinical Experience with Daptomycin for the Treatment of Patients with Osteomyelitis

American Journal of Medicine

Volumn 120, Issue 10 SUPPL. 1, 2007, Pages

  Lamp, Kenneth C ^a   Friedrich, Lawrence V ^a   Mendez Vigo, Luke ^a   Russo, Rene ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Bacteremia; Daptomycin; Methicillin resistant Staphylococcus aureus; Orthopedic device; Osteomyelitis; Vancomycin resistant enterococci

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; DAPTOMYCIN; LEVOFLOXACIN; LINEZOLID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; DATA BASE; DEBRIDEMENT; DEVICE INFECTION; DOSE RESPONSE; DRUG INFORMATION; DRUG RESEARCH; FEMALE; FOLLOW UP; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; REGISTER; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORTHOPEDIC FIXATION DEVICES; OSTEOMYELITIS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 34648836946     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.07.010     Document Type: Article

References (31)

1. Lazzarini L., Lipsky B.A., and Mader J.T. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?. Int J Infect Dis 9 (2005) 127-138
2. Lew D.P., and Waldvogel F.A. Osteomyelitis. Lancet 364 (2004) 369-379
3. Ciampolini J., and Harding K.G. Pathophysiology of chronic bacterial osteomyelitis: why do antibiotics fail so often?. Postgrad Med J 76 (2000) 479-483
4. Cunha B.A. Osteomyelitis in elderly patients. Clin Infect Dis 35 (2002) 287-293
5. Simor A.E. Containing methicillin-resistant S aureus: surveillance, control, and treatment methods. Postgrad Med 110 (2001) 43-48
6. Holtom P.D., Zamorano D., and Patzakis M.J. Osteomyelitis attributable to vancomycin-resistant enterococci. Clin Orthop Relat Res (2002) 38-44
7. Carpenter C.F., and Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38 (2004) 994-1000
8. Eisenstein B.I. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs 13 (2004) 1159-1169
9. Cubicin (daptomycin for injection). [prescribing information] (2006), Cubist Pharmaceuticals Inc, Lexington, MA
10. Mader J.T., and Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 33 (1989) 689-692
11. Rouse M.S., Piper K.E., Jacobson M., Jacofsky D.J., Steckelberg J.M., and Platelet R. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 57 (2006) 301-305
12. Finney M.S., Crank C.W., and Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin 21 (2005) 1923-1926
13. Antony S.J., Hecht M., Angelos E., and Stratton C. Clinical experience with daptomycin in patients with orthopedic-related infections. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA) (2005), Infections Diseases Society of America, Alexandria, VA 83-84 Abstract 464
14. Luu Q.N., Buxton T.B., Nelson D.R., and Rissing J.P. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol Infect Dis 8 (1989) 562-563
15. Juthani-Mehta M., Vikram H.R., Gorelick J.L., and Rappeport J.M. Successful therapy of methicillin-resistant Staphylococcus aureus (MRSA) Vertebral Osteomyelitis (VOM) with Daptomycin. Presented at the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA) (2003), Infectious Diseases Society of America, Alexandria, VA 121 Abstract 298
16. Rolston K.V.I., Segreti J.A., Lamp K.C., and Friedrich L.V. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med 120 suppl 10A (2007) S4-S5
17. Rao N., and Regalla D.M. Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res 451 (2006) 34-37
18. Burns C.A. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis (2006) 133-136
19. Dretler R., and Branch T. MRSA knee infection treated successfully with daptomycin after two failed prolonged high-dose courses of vancomycin. Infectious Diseases in Clinical Practice (2005) 327-329
20. Siegman-Igra Y., Reich P., Orni-Wasserlauf R., Schwartz D., and Giladi M. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis 37 (2005) 572-578
21. Lamp K.C., Rybak M.J., Bailey E.M., and Kaatz G.W. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 36 (1992) 2709-2714
22. LaPlante K.L., and Rybak M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48 (2004) 4665-4672
23. Vikram H.R., Havill N.L., Koeth L.M., and Boyce J.M. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 43 (2005) 5384-5387
24. Skiest D.J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44 (2006) 655-656
25. Munoz-Price L.S., Lolans K., and Quinn J.P. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 41 (2005) 565-566
26. Lewis J.S., Owens A., Cadena J., Sabol K., Patterson J.E., and Jorgensen J.H. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 49 (2005) 1664-1665
27. Hayden M.K., Rezai K., Hayes R.A., Lolans K., Quinn J.P., and Weinstein R.A. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43 (2005) 5285-5287
28. Friedman L., Alder J.D., and Silverman J.A. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50 (2006) 2137-2145
29. Tice A.D., Hoaglund P.A., and Shoultz D.A. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 114 (2003) 723-728
30. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Clinical development and labeling of anti-infective drug products. Specific Infections (2006)
31. Mader J.T., Norden C., Nelson J.D., Calandra G.B., and Infectious Diseases Society of America and the Food and Drug Administration. Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults. Clin Infect Dis 15 suppl 1 (1992) S155-S161